Silver Creek Pharmaceuticals, INC
Growth factor therapeutics to enhance cell survival
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Latest Form D
- $9.2M, Feb 2022
- Total capital
- $13M
- Federal grants
- $442K
- 2 awards · 2015
- Rank in peer group#339 of 392
- Private capital raised
- $12.6M
- 2 Form D · last Feb 2022
- 56 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 27 pending · first 2018
- Rank in peer group#9 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$9.2M
- Private capital raisedForm D · SEC · 1st filing$3.4M
- Federal grantHealth and Human S · Phase I · Protein Therapeutics Engineered to Regenerate Functional Heart Tissue$221K
- Federal grantHealth and Human S · Phase I · Protein Therapeutics Engineered to Regenerate Functional Heart Tissue$221K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
22months
from Silver Creek Pharmaceuticals, INC’s first federal award to its first private round.
- First federal award · Mar 2015
- Health and Human S · $221K
- First Form D · Dec 2016
- $3.4M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#9 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Birgit SchoeberlExecutive Officer, DirectorNamed in SEC Form D filings
- James D. MarksDirectorNamed in SEC Form D filings
- Kris D. KuchenbeckerExecutive OfficerNamed in SEC Form D filings
- Lakhmir D. ChawlaExecutive OfficerNamed in SEC Form D filings
- Mark AgneDirectorNamed in SEC Form D filings
- Michael FairbanksDirectorNamed in SEC Form D filings
Show all 12 people
- Nick J. TaylorDirectorNamed in SEC Form D filings
- Ross BreckenridgeExecutive Officer, DirectorNamed in SEC Form D filings
- Thomas J. MurtaghDirectorNamed in SEC Form D filings
- Timothy ThrosbyExecutive Officer, DirectorNamed in SEC Form D filings
- Tom MurtaghDirectorNamed in SEC Form D filings
- Ulrik NielsenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 12 granted of 39- GrantedBi-Specific Fusion ProteinsUSPTOUS 12,715,937
- GrantedBi-Specific Fusion ProteinsUSPTOUS 12,698,347
- PendingChimeric Proteins and Methods of Use for Treatment of Central Nervous System DisordersUSPTOApplication 19321375
Show all 39 patent records
- Bi-Specific Fusion ProteinsAug 25, 2026 · US 12,715,937Granted
- Bi-Specific Fusion ProteinsAug 4, 2026 · US 12,698,347Granted
- Chimeric Proteins and Methods of Use for Treatment of Central Nervous System DisordersFeb 12, 2026 · Application 19321375Pending
- Chimeric Proteins For Treatment Of Acute Radiation SyndromeMay 8, 2025 · Application 18836833Pending
- Compositions And Methods Of Treating Tissue DamageMay 8, 2025 · Application 18887949Pending
- Method Of Treating Skin Tissue Damage By Topically Administering A Bi-specific Protein Comprising A Human Insulin-like Growth Factor Variant And A Human Annexin A5 VariantOct 22, 2024 · US 12,122,819Granted
- Chimeric Proteins For Targeted Delivery Of Growth Factors To The GlomerulusAug 22, 2024 · Application 18571806Pending
- Chimeric Proteins And Methods Of Use For Treatment Of Neurodegenerative DisordersJul 25, 2024 · Application 18417568Pending
- Bi-Specific Fusion ProteinsMar 28, 2024 · Application 18483308Pending
- Bi-specific Therapeutic Proteins, In Vivo Methods Of Use Thereof And Encoding Nucleic Acids ThereofJan 23, 2024 · US 11,879,002Granted
- Bi-Specific Fusion ProteinsNov 14, 2023 · US 11,814,443Granted
- Bi-Specific Fusion ProteinsOct 12, 2023 · Application 18311306Pending
- Bi-Specific Fusion ProteinsJun 13, 2023 · US 11,673,970Granted
- Chimeric Proteins and Methods of Use for Treatment of Central Nervous System DisordersFeb 3, 2022 · Application 17390206Pending
- A Method Of Inhibiting Apoptosis Or Promoting Cell Survival By Providing A Bi-specific Protein Comprising Insulin-like Growth Factor IGF-1 And Annexin A5Oct 26, 2021 · US 11,155,593Granted
- Bi-Specific Fusion ProteinsApr 27, 2021 · US 10,988,547Granted
- Bi-specific Fusion ProteinsDec 8, 2020 · US 10,858,450Granted
- Method Of Protecting Tissue From Damage By Administering A Bi-specific Therapeutic Protein Comprising Insulin-like Growth Factor 1 (IGF-1) And Annexin A5Apr 28, 2020 · US 10,633,425Granted
- Bi-Specific Fusion ProteinsSep 10, 2019 · US 10,407,512Granted
- Bi-Specific Annexin A5/IGF-1 Proteins and Methods of Use Thereof to Promote Regeneration and Survival of TissueAug 7, 2018 · US 10,040,840Granted
- Bi-Specific Therapeutic Proteins for Tissue RepairApplication 62236169Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication 63903770Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication 19152246Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication 63723024Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication PCTUS2024014251Pending
- Chimeric Proteins And Methods Of Use For Treatment Of Neurodegenerative DisordersApplication 63597975Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication 63588481Pending
- Chimeric Proteins For Treatment Of Acute Radiation SyndromeApplication PCTUS2023062663Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication 63482904Pending
- Chimeric Proteins And Methods Of Use For Treatment Of Neurodegenerative DisordersApplication 63480547Pending
- Chimeric Proteins For Targeted Delivery Of Growth Factors To The GlomerulusApplication PCTUS2022035844Pending
- Chimeric Proteins For Treatment Of Acute Radiation SyndromeApplication 63327445Pending
- Chimeric Proteins For Treatment Of Acute Radiation SyndromeApplication 63310483Pending
- Chimeric Proteins And Methods Of Use For Treatment Of Central Nervous System DisordersApplication PCTUS2021044019Pending
- Chimeric Proteins For Targeted Delivery Of Growth Factors To The GlomerulusApplication 63216876Pending
- Chimeric Proteins And Methods Of Use For Treatment Of Central Nervous System DisordersApplication 63058888Pending
- Bi-Specific Therapeutic Proteins for Tissue RepairApplication 62322910Pending
- Bi-Specific Therapeutic Proteins for Tissue RepairApplication 62237889Pending
- Methods Of Treatment Using IGF-1 Chimeric ProteinsApplication PCTUS2025056423Pending
Related companies, and why
- NASH HOLDINGS, LLCSimilar federal contract value in Biotech · null in contracts
- PLUMB PHARMACEUTICALS, INCSimilar federal contract value in Biotech · null in contracts
- Direct Biologics, LLCSimilar federal contract value in Biotech · null in contracts
- Trasir Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Zietchick Research Institute, LLCSimilar federal contract value in Biotech · null in contracts
- ALLUVIUM BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .